Key result
Assessment of ECG-LVH, ABI, and eGFR identified target organ damage in 46% and 49% of hypertensive patients classified as low risk by SCORE and Framingham tools, respectively.
Why the study?
Does assessment of target organ damage (ABI, eGFR, ECG-LVH) improve cardiovascular risk stratification compared to conventional risk scores in hypertensive patients?
Cross-Sectional (n=495)
Does assessment of target organ damage (ABI, eGFR, ECG-LVH) improve cardiovascular risk stratification compared to conventional risk scores in hypertensive patients?
Routine assessment of ABI, eGFR, and ECG-LVH in hypertensive patients reclassifies a significant proportion of those deemed low-to-moderate risk by SCORE or Framingham into the high-risk category.
Answers are grounded in this paper and cite their sources.
May reclassify many low-risk hypertensives; hypothesis-generating for refined stratification, prospective outcome trials needed before practice change.
BACKGROUND: Recently published guidelines emphasize that detection of any subclinical target organ damage in hypertensive subjects should be regarded as a sign of high cardiovascular risk. AIM: To assess the ability of conventional multivariable cardiovascular disease risk prediction tools and high-sensitivity C-reactive protein (hs-CRP) to identify hypertensive subjects with target organ damage. METHODS: Ankle-brachial index (ABI), estimated glomerular filtration rate (eGFR), electrocardiographically determined left ventricular hypertrophy (ECG-LVH), and base-line variables were measured in hypertensive subjects aged 45-70 years without established cardiovascular or renal disease or known diabetes. RESULTS: Of the 495 subjects, 123 (24.8% (95% CI 21.1-28.9)) had ABI <1.00, 81 (16.4% (95% CI 13.2-19.9)) had ECG-LVH, and 41 (8.3% (95% CI 6.0-11.1)) had eGFR <60 mL/min/1.73 m(2). In patients with SCORE <5% or Framingham risk <20%, any sign of target organ damage was found in 46% and 49% of patients, respectively. CONCLUSION: Assessment of ECG-LVH, ABI, and eGFR reclassifies a significant number of hypertensive patients to the high-risk category as compared to SCORE and Framingham risk prediction tools only.
No takes yet. Share an insight, caveat, or question.
Korhonen et al. (2010) conducted a cross-sectional in Hypertension (n=495). Assessment of ECG-LVH, ABI, and eGFR vs. SCORE and Framingham risk prediction tools was evaluated on Presence of target organ damage (ABI <1.00, ECG-LVH, or eGFR <60 mL/min/1.73 m2). Assessment of ECG-LVH, ABI, and eGFR identified target organ damage in 46% and 49% of hypertensive patients classified as low risk by SCORE and Framingham tools, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: